Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > announces 25 million bought deal unit offering

<< Previous

Bullboard Posts

Next >>

Comment by ashcakeon Jun 09, 2020 4:02pm

350 Views

Post# 31130365

RE:RE:announces 25 million bought deal unit offering

There it is as I called it! More money required to get them through...unfortunate that it had to be at these levels,at least it was bought deal...promise for higher levels. Game is rigged againts the retail investor...always and don't forget it. Institutions sell short and buy/cover into the lower financing.

<< Previous

Bullboard Posts

Next >>

Rock Tech notches official permit for German lithium refinery